Tirzepatide Dosing in a Clinic Program: Starting Dose, Schedule and Maximum

Titration is the scheduled climb from a low starting dose to a treatment dose.

The Zepbound label's version starts at 2.5 mg once weekly, raises the dose in 2.5 mg steps, and holds each dose for at least 4 weeks before the next increase.

The climbing is the prescriber's job, not the patient's.

Zepbound is prescription-only — it takes a valid prescription from a licensed prescriber — and the label's schedule is the frame that prescription works inside: the step size and the minimum weeks per dose are fixed, while whether and when a dose actually changes is a decision the prescriber makes with the patient.

Raising a dose early, or jumping steps, puts you outside the schedule the label describes.

The pace has a reason the label's own trial tables show.

In the Zepbound weight trials, GI side effects occurred in 56% of Zepbound patients versus 30% on placebo, and most nausea, vomiting and diarrhea events happened during dose escalation and decreased over time.

The rates side by side are laid out in tirzepatide side effects.

One scope note: the schedule on this page is the Zepbound label's.

Mounjaro is the same molecule with a different label — approved for type 2 diabetes rather than weight — and its prescribing information is its own document.

What Zepbound is approved for, how clinic programs price it and how it compares with semaglutide are in our tirzepatide guide.

The starting dose is 2.5 mg injected once weekly, for 4 weeks.

The label is blunt about what that dose is for: “The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.” It is a starting rung, not a dose to stay on — the schedule moves to 5 mg once weekly after those first 4 weeks.

From there, every increase is 2.5 mg, and each dose is held for at least 4 weeks before the next step.

The label fixes the step size and the pace; it does not fix the destination.

For weight reduction, the labeled maintenance doses — 5 mg, 10 mg or 15 mg once weekly — are the stops the schedule climbs toward, and which one fits is the prescriber's call.

The dose also has a container story: Zepbound is supplied as single-dose pens and single-dose vials and, following a January 2026 label change, also as multi-dose vials and a 4-dose single-patient-use KwikPen.

One line of the label is worth knowing before a pen reaches a shared fridge: never share a KwikPen between patients, even with a new needle.

15 mg injected once weekly.

That is the top of the schedule: the Zepbound label's maximum dosage for all indications is 15 mg once weekly.

A maximum is a ceiling, not the destination the schedule is built to reach.

Labeled maintenance doses for weight reduction are 5 mg, 10 mg or 15 mg once weekly — the label treats all three as maintenance doses, which makes the choice among them a clinical one.

For moderate to severe obstructive sleep apnea in adults with obesity, the labeled maintenance doses are 10 mg or 15 mg.

That choice — which dose, and when to stop climbing — is the prescriber's to make with the patient.

“Maintenance” is inside the approved use, not an add-on.

The Zepbound label approves it, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

For weight reduction, the maintenance doses are 5 mg, 10 mg and 15 mg once weekly, and 2.5 mg is initiation only — so if treatment continues, it continues on one of those three doses.

Whether to continue, step down within the labeled options, or stop belongs with the prescriber who knows the history — it is a standing question for program check-ins rather than a solo decision.

What trials measured at each maintenance dose, and what a withdrawal trial saw when participants stopped, is covered in tirzepatide weight loss results.

The Zepbound label's missed-dose rule: take the missed dose as soon as possible within 4 days (96 hours) after it was due.

If more than 4 days have passed, the instruction is to skip the missed dose and take the next one on the usual day.

Changing the injection day has its own guardrail: when the day moves, doses must be at least 3 days (72 hours) apart.

Anything outside the rule is a question for the prescriber or the dispensing pharmacy, not something to improvise.

None of this schedule is self-serve.

Zepbound is prescription-only: it takes a valid prescription from a licensed prescriber, and FDA directs patients to fill prescriptions at state-licensed pharmacies.

Who that prescriber can be at a med spa is a state question: whether a nurse practitioner can evaluate, diagnose and prescribe independently depends on the state, which the American Association of Nurse Practitioners groups into Full, Reduced and Restricted Practice.

The rules, state by state, are laid out in who can prescribe GLP-1s.

Dosing gets confusing where compounded products are involved.

Compounded GLP-1 vials are often dosed in “units” on an insulin (U-100) syringe, and FDA explains that a “unit” there is only a volume mark — 5 units is 0.05 mL on a U-100 syringe — so the amount of drug a “unit” delivers depends on the vial's concentration, which varies from compounder to compounder.

Compounded products also have no FDA-approved label behind them: FDA does not review compounded drugs for safety, effectiveness or quality before marketing, and the agency says they should only be used when an FDA-approved drug cannot meet a patient's needs.

What compounding rules allow now, and the red flags to check for, are covered in compounded tirzepatide.